Publication: The role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal
| dc.contributor.author | YANANLI, HASAN RACİ | |
| dc.contributor.author | GÖREN, MEHMET ZAFER | |
| dc.contributor.authors | Jafarova Demirkapu, Mahluga; Yananli, Hasan Raci; Kaleli, Melisa; Sakalli, Halil Eren; Goren, Mehmet Zafer; Topkara, Betilay | |
| dc.date.accessioned | 2022-03-12T22:44:26Z | |
| dc.date.accessioned | 2026-01-11T19:05:05Z | |
| dc.date.available | 2022-03-12T22:44:26Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Opioids are effective analgaesic agents, but serious adverse effects such as tolerance and withdrawal contribute to opioid dependence and limit their use. Opioid withdrawal is a common occurrence in human opiate addicts that is not life-threatening. Studies have shown that the mesocorticolimbic system, especially the nucleus accumbens, is an important region in drug addiction and adenosine receptors play a modulatory role in the mechanism of action of drug dependence and withdrawal. The aim of this study was to investigate the effects of the selective A(1) receptor agonist CPA (N-6-cyclopentyladenosine) on withdrawal symptoms, and the concentration of dopamine and noradrenaline in the nucleus accumbens and locomotor activity behaviour during naloxone-precipitated withdrawal in morphine-dependent rats. The local administration of CPA (1.5, 3.0, and 6.0 mmol/L bilateral 250 nL) into the nucleus accumbens decreased the Gellert-Holtzman withdrawal scale, and increased concentrations of dopamine and noradrenaline in the same region during naloxone-induced withdrawal. Our findings suggest that administration of the A(1) receptor agonist significantly decreased withdrawal behaviours and increased dopamine and noradrenaline concentrations in opioid withdrawal in a dose-dependent manner. These results demonstrate that adenosine receptors should be examined as a potential mechanism that could be exploited for the treatment of morphine withdrawal. | |
| dc.identifier.doi | 10.1111/1440-1681.13224 | |
| dc.identifier.eissn | 1440-1681 | |
| dc.identifier.issn | 0305-1870 | |
| dc.identifier.pubmed | 31808190 | |
| dc.identifier.uri | https://hdl.handle.net/11424/236429 | |
| dc.identifier.wos | WOS:000508566100001 | |
| dc.language.iso | eng | |
| dc.publisher | WILEY | |
| dc.relation.ispartof | CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | adenosine | |
| dc.subject | CPA | |
| dc.subject | dopamine | |
| dc.subject | morphine | |
| dc.subject | noradrenaline | |
| dc.subject | nucleus accumbens | |
| dc.subject | ADENOSINE A(1) RECEPTORS | |
| dc.subject | D-ASPARTATE RECEPTOR | |
| dc.subject | SYNAPTIC-TRANSMISSION | |
| dc.subject | MEDIATED MODULATION | |
| dc.subject | OPIATE WITHDRAWAL | |
| dc.subject | PREFRONTAL CORTEX | |
| dc.subject | DOPAMINE RELEASE | |
| dc.subject | A(2A) RECEPTORS | |
| dc.subject | GABA RELEASE | |
| dc.subject | RAT | |
| dc.title | The role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 560 | |
| oaire.citation.issue | 4 | |
| oaire.citation.startPage | 553 | |
| oaire.citation.title | CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | |
| oaire.citation.volume | 47 |
